Held by 6 specialist biotech funds
High Convergence# Signal Note: Avoro Capital Initiates $119.3M Position in TSHA Avoro's entry signals conviction in Taysha's gene therapy pipeline, particularly TSHA-101 for GM1 gangliosidosis and TSHA-102 for GM2 gangliosidosis—rare lysosomal storage disorders with high unmet need and potential for accelerated pathways.
AI analyst context — unlock full analysis
**Signal Note: RA Capital initiates $129.6M position in TSHA** RA Capital's substantial entry into Taysha signals confidence in its pipeline of AAV gene therapies for rare neurological diseases, particularly giroctocogene fitelparvovec (TSHA-101) for hemophilia A and programs in SMA and other CNS indications. The timing suggests conviction ahead of near-term clinical readouts or regulatory decisions that could validate the platform's durability and manufacturing scalability—key de-risking events for gene therapy investors.
+ 4 more positions with dollar amounts and AI context
Unlock All — 7-Day Free Trial